Thoratec ([[THOR]] +5.3%) trades higher today after Wells Fargo ups the shares to Outperform and raises its valuation by roughly 20%. The move comes a day after the FDA approved rival HeartWare ...
Thoratec ( THOR +5.3% ) trades higher today after Wells Fargo ups the shares to Outperform and raises its valuation by roughly 20%. The move comes a day after the FDA approved rival HeartWare International's ( HTWR -5.4% ) heart-pumping device, and Wells notes that THOR 's competing product showed ...
Read the rest of this article on SeekingAlpha.com: SA Currents
Related Videos
-
Wells Fargo Succeeds by Keeping It SimpleWells Fargo does a good job of executing the old banking mantra: pay depositors 3%, lend at 6%, and be on the golf course by 3 p.m.
-
Dorsey: Two Simple Reasons to Own Wells FargoTwo advantages and a compelling valuation make this bank worth holding, says Morningstar's director of equity research.
-
Meantime Could Be Lean Time for Wells Fargo StockT2 Partners' founder and 'Mortgage Meltdown' author Whitney Tilson says Wells Fargo could be worth $60 per share, but the road just ahead will be rocky.
-
Wells Has Great Dividend PotentialJosh Peters thinks Wells Fargo will use its earnings power to greatly expand its dividend now that it has paid back its TARP funds.